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ABSTRACT
A recent method using Dynamic Linear Models to improve preferred treatment
allocation budget in random allocation models was proposed by [1]. However this
model failed to include the impact covariates such as smoking, gender, etc, had on
model performance. The current paper addresses random allocation to treatments
using the DLM in Bayesian Adaptive Allocation Models with a single covariate. We
show a reduced treatment allocation budget along with a reduced time to locate
preferred treatment. Furthermore, a sensitivity analysis is performed on mean and
variance parameters and a power analysis is conducted using Bayes Factor. This
power analysis is used to determine the proportion of unallocated patient budgets
above a specified cutoff value. Additionally a sensitivity analysis is conducted on
covariate coefficients.
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1. Introduction
Clinical trials are popular research methods used to determine a preferential treat-
ment when more than one possible treatment exists by reducing between group bias.
These treatments are randomly assigned to groups of patients receiving a particular
treatment. According to Zelen [2] these groups “are as similar as possible except for
the administered treatment whereby the groups are decided through randomization”.
Randomization procedures in clinical trials have been extensively researched, and while
assigning an equal number of patients to each treatment is the most common method,
ethical issues using this method were discussed by [3].
Ideally, a sequential allocation of patients to treatments through a random method
which skews patients to the most effective treatment while retaining a fully randomized
process is preferred. This process, known as random allocation, has been extensively
researched. This research includes the early works of [4–6]. Further research led to
the Play the Winner Rule of [7], and its modifications made by [8]. Additional works
include those of [3,9]. A Bayesian approach was used by [10] to compare the works of
both [11] and [12] for binary outcomes.
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Another method which has been used in random allocation processes involves adap-
tively allocating subjects between treatments through the Bayesian Adaptive Design.
Here, Bayesian updating methods are used to allocate subjects to treatments. This
design involves transforming updated information into prior information through re-
peated updating. According to Thall and Wathen [12] this ability provides “a nat-
ural framework for making decisions based on accumulating data during a clinical
trial”. Likewise, Berry [13] indicated Bayesian updating ability provided “the ability
to quantify what is going to happen in a trial from any point on (including from the
beginning), given the currently available data”. There has been much research done
in this area including the works of [14–17]. Additionally, the works of Sabo [18] illus-
trated a Bayesian approach to create what he termed “Decreasingly Informative Prior”
information. This was used to evaluate the adaptive allocation performance when us-
ing binary variables. Recently, [1] used a Dynamic Linear Model approach to random
allocation, and demonstrated reduced time and patient budget used to identify the
preferred treatment.
Often with human subjects however, there exist covariates such as smoking, age,
or sex to mention a few, which may impact the response. It is therefore imperative
to include these covariates, provided they exist, when randomly allocating subjects to
treatments. The literature for covariate influenced adaptive allocation is quite sparse.
The idea of DA optimality was discussed by [19] for a biased coin design method, how-
ever, this did not include the random allocation. The works of [20] compared several
random allocation methods, however, they did not include any covariate influences.
Although [21] used normal responses, they failed to consider the influence of covariates.
A covariate adjusted method was proposed by [22] for the Doubly Adaptive Biased
Coin Design, however, it looked at the variability reduction rather than the alloca-
tion methods. An examination of the asymptotic properties along with a theoretical
examination may be seen in [23], however, as with the previous authors, no random
allocation was completed. However, [24] were able to use their method when covariates
were present.
When investigating the impact of a single covariate, let y patients enter a random
allocation study sequentially at different times each with a single covariate x. These
yt patients and their xt covariates may then be considered components of a time se-
ries. Additionally, patient budget size is set to be a total of N patients during the
trial such that T is the index set for patient yt with covariate xt measured in a total
of N patients. As these sequentially entering yt patients enter the allocation study
updating procedures provide additional allocation information regarding treatment
effectiveness toward the better treatment. Using a Bayesian Adaptive Design creates
a Bayesian Learning Method, whereby information regarding the better treatment
is learned as more patients enter the study. This information may then be applied
to entering patients. For instance, increased information regarding the better treat-
ment may be applied to patient y15 through the updated information which occurred
through patient y14. Thus more information is known at patient y15 than at patient
y14, and as information is updated, the Bayesian design learns the better treatment.
The aforementioned allocation method is capable of allocating subjects to treatments
when these covariates exist.
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Bayesian Methods
Numerous works exist whereby Bayesian methodologies have been applied. Some of
these works include theoretical texts by [25] who applies Bayesian ideas to sampling
methodologies. Additional works include those of [26] who illustrates how to apply
Bayesian methods using the R programming language in combination with a theoreti-
cal overview. A discussion on Bayesian Loss functions may be found in [27], while [28]
chapter 1 provides an additional introduction.
The basic premise surrounding Bayesian methods is known as Bayes rule, named
after Rev. Thomas Bayes. The idea posed by Bayes was
p(θ|y) = p(θ)p(y|θ)/p(y) (1)
where p(θ|y) represents the posterior distribution of θ given the known y data. Likewise
p(θ)p(y|θ) ∝ p(θ, y) (2)
Here, p(θ) is defined to be the prior probability of the parameter θ by Gelman
et al. [25] and p(θ, y) is the conditional probability involving θ and y. Furthermore,
by conditioning on the known y data, the sampling distribution probability, p(y|θ)
provides the posterior probability (See [25] for more details.) Additional work using
these ideas in the application of time series data has been done by [28]. Yet, once the
posterior probability p(θ|y) has been calculated, it may then be used as a new prior
probability and the process repeated, with the Bayesian Updating learning along the
way.
The Dynamic Linear Model (DLM) of Harrison and West [29] uses this updating
process to create a Bayesian Learning Process. The learning ability created by this up-
dating provides a useful mechanism whereby the DLM may forecast the y observations
such that
Yt = F
′
tθt + νt (3)
θt = Gtθt−t + ωt
where
νt ∼ N(0, Vt) (4)
ωt ∼ N(0,Wt)
As defined both by Harrison and West [29], and previously in [1] θt represent the
forecast parameter Ft where Ft is a known n× r matrix of independent variables, Gt
is a known n× n system matrix, Wt is a known n× n evolution variance matrix, and
Vt is a known r × r observational variance matrix.
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The prior forecast parameter θt is found by noting (θt−1|Dt−1) ∼ N(mt−1, Ct−1)
for some mean mt−1 and variance matrix Ct−1. The prior for θt may be seen
to be (θt|Dt−1) ∼ N(at, Rt) whereby at = Gtmt−1 with Rt = GtCt−1G′t +Wt.
The one step ahead forecast is calculated as (Yt|Dt−1) ∼ N(ft, Qt). Here, ft is
the current treatment allocation for patient y, while Qt is the forecast allocation
variance for patient y. The posterior for θt relies on (θt−1|Dt−1) ∼ N(mt, Ct)
Furthermore, mt = mt−1 +Atet, where mt represents the current mean matrix,
Ct = Rt −AtQtA′t where Ct is the current variance matrix, At = RtFtQ−1t where
At is the adaptive coefficient, and et = Yt − ft represents the error term.
Random Allocation Methods
There have been several methods used to minimize allocation responses. One such
solution was proposed by [20], who suggested using
wA =

QAt
√
fBt
QAt
√
fBt+QBt
√
fAt
if (fAt < fBt |
QAt
√
fBt
QBt
√
fAt
> 1)
QAt
√
fBt
QAt
√
fBt+QBt
√
fAt
if (fAt > fBt |
QAt
√
fBt
QBt
√
fAt
< 1)
1
2 Otherwise
(5)
wB = 1− wA
to determine the optimally weighted allocation value solution. This solution was
shown by [21] to be problematic because it was possible for fAt or fBt to be negative,
therefore Biswas and Bhattacharya [21] proposed their optimal solution
ωA =
QAt
√
fBt
QAt
√
fBt +QBt
√
fAt
(6)
ωB = 1− ωA
where γA = Φ
 fAt − fBt√
Q2At +Q
2
Bt
 , γB = Φ
 fBt − fAt√
Q2At +Q
2
Bt

Recently, [30] examined how a Decreasingly Informative Prior distribution impacted
the allocation using each of these equations. The DLM was applied by [1] and used to
compare the allocation results between the two equations using no covariate. In the
current work a covariate is included and a comparison made. Because the DLM is an
updating method at each value, the values for each of fAt , fBt , QAt , QBt will change
at each iteration, leading to different weight values based on the starting values. For
this application, the covariate was generated as a Uniform (0,1) random variable.
Alogrithm
To generate the allocation values
(1) Initiate the DLM for µA, µB, ωt, CtA , CtB , QtA , QtB .
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(2) Identify xt and calculate predicted values and variances fAt (Ft = [1, 0]), fBt
(Ft = [1, 1, xt]), QAt and QBt
(3) Compute wA and wB
(4) Sample a Uniform(0,1) random variable U and compare wA
(5) If wA < U , allocate to Treatment A (Ft = [1, 0]), otherwise allocate to treatment
B (Ft = [1, 1, xt])
(6) Conduct experiment and observe yt
(7) Update the DLM and return to step 2
Simulation Study
The seven scenarios in Table 1 were investigated by [30] using the Decreasingly Infor-
mative Prior and then by [1] using the DLM and including a covariate. Each group
randomly allocated each scenario through 1000 simulations, and the treatment allo-
cation probabilities, total number of allocations in each treatment group, and total
number of successes was recorded. However, the current authors have only included
the treatment allocation associated with the preferred treatment and these may be
seen in Table 2. The Decreasingly Informative Prior Method of [30] utilized manual
iterations for each iteration. This lead to an sizable number of simulated calculation
runs which lead to considerable completion times. The method of [1] was applied with
a covariate added to the model and these times were greatly reduced. Each scenario
was run using R Studio version 1.2.1335 on an ACER computer with an AMD Ryzen 5
2500U with Radeon Vega Mobile Gfx 2.00 GHz processor and 8.00 GB of RAM using
Windows 10. The mean run time was approximately 120.259 seconds to completion.
The lowest run time to completion was 60.960 seconds using the budget size N = 34.
The highest run time to completion was 120.690 seconds using budget size N = 200,
Table 1. Simulation Scenarios
Scenario Differences Standard Deviation Planned Sample Budget
1 0 20 128
2 10 15 74
3 10 20 128
4 10 25 200
5 20 20 34
6 20 25 52
7 20 30 74
An analysis was conducted using each of the values in Table 1 and the allocation
values may be observed in Table 2. The mean number of allocations was obtained
using each method. Notice the mean allocation using equation 5 attributed to [20] was
63.542, which is as expected, given the probability of allocation to Treatment A was 0.5.
The equal treatment allocation proportion for µB = 0, standard deviations = 20 and
budget size N = 128 may be observed in Figure 1a. However, when the unequal method
of [21] in equation 6 was applied to the same parameters, the mean number applied
to Treatment A is 96.716, while the mean number allocated to Treatment B is 31.284.
The proportion results for equation 10 may be observed in Figure 1b. Here the mean
allocation proportion for treatment A was 0.654, while mean allocation proportion to
treatment B was 0.346. Additionally it is important to note the immediate convergence
to either 0 or 1 using these values. Under the methods of [20,21,30], the smaller value
5
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(b) Unequal Allocation.
Figure 1. Comparison Between Equal and Unequal Allocation With Covariates.
was taken to be the better allocation, therefore, it appears as though Treatment B is
the favorable treatment.
Table 2. Treatment Group Mean Sample Size. Italicized values indicate Treatment B was selected
Mean SD Sample Equation 5 Equation 6
Difference Budget Allocation Allocation B
0 20 128 63.542 31.284
10 15 74 36.545 6.038
10 20 128 63.690 8.056
10 25 200 99.064 10.833
20 20 34 16.641 3.314
20 25 52 25.652 3.900
20 30 74 36.479 4.379
Similar to [1] the mean, system variance and observational variance were varied to
determine treatment allocation weight behavior. The modifications made to these pa-
rameter values will aid researchers in determining a early stopping criterion through
early favorable treatment identification. This early stopping criterion will enable the
avoidance of the ever-present ethical issues seen with unfavorable treatment assign-
ment.
A budget size of N = 100 was chosen and a sensitivity analysis was conducted using
various values for δt, ωt, and ctB , while keeping Qt = 1. The values chosen for µB were
1 - 5, leading to HA : δt = 1 through HA : δt = 5. This lead to the hypothesis
H0 : δt = 0
HA : δt 6= 0 (7)
where δt = µA − µB such that δt = 1, 2, 3, 4, 5. Furthermore, ωt = 0.1, 0.01, 0.001, and
ctB = 0.1, 0.001, 0.000001. Decreasing the values for ωt represents an increased cer-
tainty of between time variability impact. Finally, decreasing the values of ctB results in
an increased knowledge group B has no effect. The weighted allocation proportion val-
6
ues in Figure 2 represent each of the δt and ωt values. However only the ctB = 0.000001
was chosen because it provides the best illustration of the impact seen in the sensi-
tivity analysis. Additionally, by using N = 100 and retaining Qt = 1 throughout the
sensitivity analysis the varied values of δt represent 1% to a 5% difference in the two
treatments.
The first analysis used δt = 1 with ωt = 0.1 and the results are shown in Figure 2a.
Using these values treatment A had a mean proportion of allocation of 0.603 with
treatment B allocation proportion equal to 0.397. The treatment allocation switch
from B to A had a mean value of 39.595. When ωt = 0.01 in Figure 2b the mean
proportion of allocation values to treatment A decreased to 0.595, while treatment
B allocation increased to 0.405. However, the mean allocation switch from B to A
increased slightly from 39.595 to 40.913. Finally, Figure 2c provides the results when
letting ωt = 0.001. Here the mean proportion of allocation values to treatment A was
0.538 with that allocated to treatment B equal to 0.462. Using δt = 1 and patient entry
time variances this accurate lead to the highest mean treatment allocation switch from
B to A, 46.702.
Next δt = 3 was chosen and the analysis was conducted. Using ωt = 0.1 treatment A
had a mean proportion of allocation of 0.793, with treatment B allocation proportion
equal to 0.207, seen in Figure 2d. The treatment allocation switch from B to A had a
mean value which decreased from 39.595 using δt = 1 to 18.217 using δt = 3. When
ωt = 0.01, seen in Figure 2e, the mean proportion of allocation values to treatment
A decreased to 0.751, while treatment B allocation increased to 0.249. However, the
mean allocation switch from B to A decreased from 40.913 at δt = 1 to 24.694 using
δt = 3. Finally, Figure 2f shows the results when ωt = 0.001. Here the mean proportion
of allocation values to treatment A decreased to 0.609 with mean proportion allocated
to treatment B equal to 0.391. Once again the mean number at which the treatment
allocation switched from B to A decreased from 46.702 using δt = 1 to 39.499 using
δt = 3.
Finally δt = 5 was analyzed using the varied ωt values. Using ωt = 0.1 treatment A
had a mean proportion of allocation of 0.885, with treatment B allocation proportion
equal to 0.115, seen in Figure 2g. The mean number at which treatment allocation
went from B to A was 8.159, which is much lower that the mean values for ωt = 0.1
when using δt = 1 or 3. When ωt was decreased to 0.01, seen in in Figure 2h, the mean
proportion of allocation values to treatment A decreased slightly to 0.833, while treat-
ment B increased to 0.167. The mean number at which treatment allocation switched
from A to B was 15.453, almost double that obtained using ωt = 0.1. Lastly, Figure 2i.
shows the allocation weights when the value for ωt was chosen to be 0.001. Here treat-
ment A had a mean allocation proportion allocation of the mean proportion of 0.665,
while treatment B had a mean allocation proportion of 0.335, seen in Figure 2o. Using
the more precise patient entry time variances, treatment allocation switched from B
to A was 33.482, which is double the value at ω = 0.01 and 4 times that when ω = 0.1.
By decreasing the value of ωt within each δti , it can be seen the mean allocation
probabilities to treatment A decrease within each group, leading to lower convergent
values in each δt group, i.e. when δt = 1 the mean convergent values for treatment
A go from 0.603, 0.595, 0.538 as information regarding ωt became more precise. This
indicates a higher treatment B allocation proportion. However, increasing δt also leads
to an increased mean number of necessary allocations for more precise ωt. For instance,
when δt = 3, the number of allocation values are 18.217, 24.694, and 39.499 for ω =
0.1, 0.01, 0.001 respectively. However, when each of the allocation values are compared
with comparable values of ωt at each δt value, one may observe a diminished mean
7
number for comparable values of ωt. For example, when allowing ωt = 0.1, the mean
number goes from 39.595 at δt = 1 to 18.217 at δt = 3 to 8.159 when δt = 5. In fact,
it appears using δt = 5 provides the lowest mean switching value at every comparable
value of ωt.
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(a) δt = 1, ωt = 0.1.
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(b) δt = 1, ωt = 0.01.
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(c) δt = 1, ωt = 0.001.
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(d) δt = 3, ωt = 0.1.
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(e) δt = 3, ωt = 0.01.
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(f) δt = 3, ωt = 0.001.
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(g) δt = 5, ωt = 0.1.
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(h) δt = 5, ωt = 0.01.
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(i) δt = 5, ωt = 0.001.
Figure 2. Comparison of Weight Allocation proportions for ωt = 0.1, 0.01 and 0.001 and δt = 1, 3, 5, CtB =
0.000001 and βt = 1 with bars representing the uncertainty across simulations.
2. Stopping Rule
In order to maintain a fully Bayesian approach to this research, a Bayes Factor was
used to determine definitive results. Additionally the 95% credible intervals and the
associated medians were calculated and were used, along with the Bayes Factor, to
determine when the algorithm flipped treatment assignment. In order to determine
a “critical” Bayes Factor value, [31], suggest using a Bayes Factor greater than 100
provides “Decisive evidence” against the null hypothesis of no difference. However,
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the notation of [32] was used for the calculation of the Bayes Factor, whereby the null
hypothesis is in the numerator yielding
p(H0 | (D)) = P (D | H0)P (H0))
P (D | H0)p(H0) + P (D | H1)p(H1) (8)
In their definition, they have the null hypothesis in the numerator and this leads to
the Bayes Factor
BF01 =
P (D | H0)
P (D | H1) (9)
Using equation 9, a Bayes Factor less than 1100 was chosen to provide “Decisive
evidence” and support towards the more favorable treatment.
The Bayes Factor was calculated using the Bayesian Two Sample T-Test discussed
in [32]. They define the Bayes Two Sample T Test as
BF =
Tν(t | 0, 1)
Tν(t | n
1
2
δ λ, 1 + nδσ
2
δ )
(10)
By choosing a Bayes Factor less than 1100 any Bayes Factor considered “Decisive”
represented a 100 times more likely chance the allocation had switched. Any indecisive
Bayes Factor indicated the budget size N = 100 was exhausted and no treatment
allocation switch had occurred. Parenthetical values in Table 3 and Table 4 represent
median and 95% credible interval values of the Bayes Factor while the bold numbers
represent the Bayes Factor calculated at N = 100.
Using the value ctB = 0.000001, a sensitivity analysis was conducted using δt = 1, 3
and 5 when varying ωt. These median, 95% credible intervals, and Bayes Factors
may be seen in Table 3 and Table 4. Any italicized Bayes Factor is considered highly
decisive, and represents 100 times more likely a switch occurred.
Table 3. Covariate Included Budget Allocation N using δt = 1, 2, 3 (Q0.025, Q0.5, Q0.975) P(N ≥ 100)
δt
Ct ωt 1 2 3
0.1
0.1 (25, 48, 84), 0.002 (22, 32, 51), 0.000 (22, 28, 45.025), 0.001
0.01 (47, 72, 100), 0.106 (44, 55, 74), 0.000 (48, 56, 69.025), 0.000
0.001 (99, 100, 100),0.974 (100,100,100),0.985 (76, 90, 100),0.166
0.001
0.1 (27, 49, 86.025), 0.009 (21, 31, 48), 0.000 (23, 28, 46), 0.000
0.01 (50, 73, 100), 0.105 (46, 58, 75), 0.000 (49, 57, 68.025), 0.000
0.001 (100,100,100),1.000 (100,100,100),1.000 (98,100,100),0.956
0.000001
0.1 (26.975, 47, 87), 0.009 (23, 32, 52), 0.000 (22, 27.5, 43), 0.000
0.01 (50, 74, 100), 0.114 (47, 57, 76), 0.001 (49.975, 57, 69), 0.000
0.001 (100, 100, 100),1.000 (100, 100, 100),1.000 (99, 100, 100),0.974
Notice at ωt = 0.1 the Bayes factor for δt = 1 is 0.009 (median =47, 95% credible
interval (26.975, 87)), while for δt = 2 the Bayes Factor is 0.000 (median = 32, 95%
credible interval (23, 52)). When analyzing δt = 3, a Bayes Factor of 0.000 was calcu-
lated (median = 27.5, 95% credible interval (22, 43)) An increase to δt = 4 yielded a
9
Bayes Factor of 0.010 (median = 28, 95% credible interval (23, 73.025)). Each of these
first 4 means indicated decisive evidence. However, when δt = 5 the Bayes factor is
0.088 (median = 32, 95% credible interval (25, 100)), indicating indecisive evidence
suggesting no switch to the better treatment occurred prior to exhausting the patient
budget size.
Table 4. Budget Allocation using N using µB = 4, 5 (Q0.025, Q0.5, Q0.975) P(N ≥ 100)
µB
Ct ωt 4 5
0.1
0.1 (22.000, 29.000, 78.025),0.010 (25.000, 32.000,100.000), 0.113
0.01 (50.000, 61.000, 76.000), 0.001 (45.000, 56.000, 85.000), 0.002
0.001 (63.000, 75.000, 94.000), 0.011 (57.000, 68.000, 87.000), 0.000
0.001
0.001 (24.000, 28.000, 68.025), 0.006 (26.000, 31.000, 100.000), 0.074
0.01 (50.000, 60.000, 73.000), 0.000 (46.000, 55.000, 73.000), 0.000
0.001 (86.000, 94.000, 100.000), 0.203 (78.000, 86.000, 99.000), 0.021
0.000001
0.1 (23.000, 28.000, 73.025), 0.010 (25.000, 32.000, 100.000), 0.088
0.01 (49.000, 61.000, 76.000), 0.000 (45.000, 56.000, 76.025), 0.002
0.001 (85.000 ,94.000, 100.000), 0.223 (79.000, 87.000, 100.000), 0.027
When ωt was reduced to 0.01, using δt = 1 a Bayes Factor of 0.114 (median =
74, 95% credible interval (50, 100)) was calculated indicating no decisive evidence of
preferred treatment was found by N = 100. Yet, when δt = 2 a Bayes Factor of 0.001
(median = 57, 95% credible interval (47, 76)) indicated decisive evidence. Decisive
evidence was also seen when δt = 3 with its Bayes Factor of 0.000 (median = 57,
95% credible interval (49.975, 69)). Interestingly, using the value of δt = 4 and δt = 5
yielded Decisive Bayes Factors (0.000 and 0.002 respectively), which provided highly
decisive evidence the allocation to the better treatment had occurred. However, using
δt = 4 median value was 61 (95% credible interval 49, 76.000), while with µB = 5 a
lower median value of 56 was observed with 95% credible interval (45, 76.025).
Lastly, when ω = 0.001 was analyzed, the Bayes Factor for δt = 1 and δt = 2 were
the same; a value of 1.000 which indicated no decisive evidence was found. Additionally,
each had the same median and 95% credible interval values of 100. The Bayes Factor
decreased to 0.974 (median = 100, 95% credible interval (99, 100)) when δt = 3,
however this was also indecisive. Likewise, even though the Bayes Factors decreased
dramatically when δt = 4, 5 (Bayes Factors of 0.223 and 0.027 respectively), no decisive
evidence was found with these means either. However, when δt = 4 median value was
94 with 95% credible interval values (85, 100), however, when µB = 5, median value
was 87, with 95% credible interval values (79, 100).
This analysis provides insight into how researchers may plan patient budget sizes.
When choosing mean difference values between 1 and 3, it appears as though using
the mean difference of 3 provides the lowest median and credible interval values using
low to moderate belief in the variability between patients. However, it appears as
though δt = 5 provides the lowest median value when using a moderate variance
of ωt = 0.01 using ctB = 0.000001. Furthermore, when using the highest variance
accuracy of ωt = 0.001, there is no Decisive evidence shown for any choice of mean
at ctB = 0.000001. Likewise, using ωt = 0.01 showed Decisive evidence for all mean
values except δt = 1
10
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(a) µB = 1, βt = 1.
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(b) µB = 1, βt = 2.
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(c) µB = 3, βt = 1.
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(d) µB = 3, βt = 2.
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(e) µB = 5, βt = 1.
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(f) µB = 5, βt = 2.
Figure 3. Weight Allocation Proportion Comparisons when µB = 1, 3, 5, ωt = 0.1, ctB = 0.000001 and
β = 1, 2 The bars represent the uncertainty across simulations
3. Covariate Comparison
A comparison of the mean proportional allocation to treatments was also conducted
when using values of β = 1, 2. This comparison was conducted using δt = 1, 3, 5,
ωt = 0.1 and ctB = 0.000001. The results when comparing β = 1 and β = 2 for each
of the δt, ωt, ctB may be seen in Figure 3 and the results of the Bayes Factor may be
seen in Table 5. For the graphs of δt = 1, 2, 3, 4, 5, ωt = 0.1 and ctB = 0.000001, please
see Figure 4 in Appendix A.
When using δt = 1 and βt = 1 the mean proportion allocation for treatment A is
0.608, while the mean proportion allocation for treatment B is 0.392. However, when
βt is increased to 2, the mean proportion allocation for Treatment A shows only a
slight decrease to 0.604 while the mean proportion allocation for treatment B is 0.396,
illustrating when using δt = 1 there is very little change in allocation proportion based
on the change in covariate value from 1 to 2. Likewise, the allocation switch from
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Table 5. Budget Allocation using N using µB = 4, 5 (Q0.025, Q0.5, Q0.975) P(N ≥ 100) for βt = 1, 2
βt
δt 1 2
1 (27.000, 50.000, 86.025), 0.008 (26.000, 49.000, 88.025), 0.007
3 (23.000, 28.000, 43.025), 0.000 (21.000, 28.000, 44 ), 0.000
5 (26.000, 32.000, 100.000), 0.083 (26.000, 31.000, 100.000), 0.084
B to A using βt = 1 was 39.813, with a similar value of 39.554 when using βt = 2,
indicating changing the covariate value had little impact on when the switch from B
to A occurred.
When using δt = 3 and βt = 1 the mean proportion allocation for treatment A is
0.791, while the mean proportion allocation for treatment B is 0.209. However, when βt
is increased to 2, these allocation proportions remain the same illustrating when using
δt = 3 there is no change in allocation proportion when the covariate value increases
from 1 to 2. Likewise, the allocation switch from B to A using βt = 1 was 18.568,
with a similar value of 18.544 when using βt = 2. This again indicates increasing the
covariate value from 1 to 2 has little to no impact on when the algorithm will switch
from B to A.
When using δt = 5 and βt = 1 the mean proportion allocation for treatment A
is 0.888, while the mean proportion allocation for treatment B is 0.112. However,
when βt is increased to 2, the mean proportion allocation for Treatment A shows only
a slight increase to 0.889 while the mean proportion allocation for treatment B is
slightly decreased to 0.111, illustrating when using δt = 5 there is very little change in
allocation proportion when βt is increased from 1 to 2. Likewise, the allocation switch
from B to A using βt = 1 was 8.359, with a similar value of 8.375 when using βt = 2.
Similar to both δ = 1 and δ = 3 this indicates increasing the covariate value from 1
to 2 has little to no impact on when the algorithm will switch from B to A.
Finally, the median and 95% credible intervals and Bayes Factor were calculated
for for δ = 1, 3, 5 and βt = 1, 2 and these may be seen in Table 5. Note that when
δ = 1 and 3, decisive Bayes factors were found at both βt = 1 and 2. The median
value for the combination δt = 1 and βt = 1 was 50 (95% credible interval 27.000,
86.025) with a Bayes factor of 0.008, while when βt = 2 the median was 49.000 (95%
credible interval 26.000, 88.025) with a Bayes factor of 0.007. When δt is increased
to 3, the median value decreases to 28 (95% credible interval 23.000, 43.025) with a
Bayes factor of 0.000 using βt = 1, yet when βt = 2, while the median value of 28
remains unchanged, the 95% credible interval ranges from 21.000 to 44.000, and the
Bayes factor value of 0.000 remains unchanged. Finally, when δt is increased to 5, a
median value of 32.000 is found using βt = 1 with 95% credible interval 26.000, 100.00
and an indecisive Bayes factor of 0.083. When βt is increased to 2, the median value
only slightly changes from 32 to 31, however, the 95% credible interval values remain
unchanged (26.000, 100.000), again with an indecisive Bayes factor of 0.084.
Conclusion
Researchers conducting Bayesian Random Allocation models for clinical trials can be
faced with computationally intensive problems when running large scale simulations
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requiring MCMC methods. These models are further complicated when a covariate
is introduced. In the current application, a DLM was applied to random allocation
models with a single covariate to demonstrate the ability to reduce time and patient
allocation size in the presence of a covariate. Additionally, a sensitivity analysis was
conducted both on mean proportion of allocation to each treatment and mean value
required to switch to the preferred treatment. This provides insight for researchers who
wish to know what treatment allocation proportion may be expected using varying
difference values between µA and µB, between time variances ωt and current treatment
B variance ctB , thereby providing insight into the different model behaviors. Likewise,
a power analysis was conducted using a Bayes Factor. This power analysis indicated
the lowest median Bayes Factor occurred for a difference δt = 5 using ωt = 0.01.
This provides insight into necessary patient budget to determine a favorable treatment
identification stopping criterion. This reduction of patient budget should reduce, if not
eliminate the ethical issues caused by the increased unfavorable treatment allocation
necessary using other allocation methods by allowing the more favorable treatment
to be applied earlier in the clinical trial. Additionally, covariate values of 1 and 2
were analyzed using δt = 1, 3, 5 while holding ωt = 0.1 and ctB = 0.000001 and a
power analysis conducted using these values. It appears δt = 3 provides the lowest
median and the most decisive Bayes factor, regardless of which βt is chosen. Likewise,
it appears that increasing βt from 1 to 2 has little to no impact on model performance.
Future works may include a sensitivity analysis using multiple values for β with larger
differences than an increase of 1 unit. Additionally an examination of multi-arm studies
with covariates, and survival analysis applications should be studied.
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(a) µB = 1, βt = 1 (b) µB = 1, βt = 2
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(c) µB = 2, βt = 1 (d) µB = 2, βt = 2
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(e) µB = 3, βt = 1 (f) µB = 3, βt = 2
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(g) µB = 4, βt = 1 (h) µB = 4, βt = 2
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(i) µB = 5, βt = 1 (j) µB = 5, βt = 2
Figure 4. Weight Allocation Proportion Comparisons when µB = 1, 2, 3, 4, 5, ωt = 0.1, ctB = 0.000001 and
β = 1, 2 The bars represent the uncertainty across simulations
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